FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119707932> ?p ?o ?g. }

• W3119707932 endingPage "185" @default.
• W3119707932 startingPage "172" @default.
• W3119707932 abstract "Paclitaxel, a widely used anti-cancer drug, is frequently associated with prolonged and severe peripheral neuropathies (PIPN), associated with neuroinflammation. Currently, PIPN effective treatments are lacking. Peroxisome Proliferator-Activated Receptor-α (PPAR-⍺) can modulate inflammatory responses. Thus, the use of PPAR-⍺ agonists, such as fibrates (fenofibrate and choline-fenofibrate), currently used in dyslipidemia treatment, could represent an interesting therapeutic approach in PIPN.Our studies tested the efficacy of fenofibrate (150 mg/kg, daily, i.p.) and choline fenofibrate (60 mg/kg daily, p.o.) in reversing and preventing the development of PIPN (paclitaxel: 8 mg/kg, i.p., every other day for 4 days) in male and female C57BL/6J mice. Mechanical and cold hypersensitivity, conditioned place preference, sensory nerve action potential (SNAP), as well as the expression of PPAR-⍺, TNF-⍺, IL-1β and IL-6 mRNA were evaluated.While fenofibrate treatment partially reversed and prevented the development of mechanical hypersensitivity, this was completely reversed and prevented by choline-fenofibrate. Both fibrates were able to completely reverse and prevent cold hypersensitivity induced by paclitaxel. The reduction of SNAP amplitude induced by paclitaxel was also reversed by both fenofibrate and choline-fenofibrate. Our results indicate that suppression of paclitaxel-induced hypersensitivity by fibrates involves the regulation of PPAR-⍺ expression and decrease neuroinflammation in DRG. Finally, the co-treatment of Paclitaxel and fenofibric acid (fibrates active metabolite) was tested on different cancer cell lines, no decrease in the antitumoral effect of paclitaxel was observed.Taken together, our results show for the first time the therapeutic potential (prevention and reversal) of fibrates in PIPN and opens to a potential pharmacological repurposing of these drugs." @default.
• W3119707932 created "2021-01-18" @default.
• W3119707932 creator A5007967344 @default.
• W3119707932 creator A5014707832 @default.
• W3119707932 creator A5015383366 @default.
• W3119707932 creator A5029671075 @default.
• W3119707932 creator A5030544754 @default.
• W3119707932 creator A5037907585 @default.
• W3119707932 creator A5038391772 @default.
• W3119707932 creator A5038514683 @default.
• W3119707932 creator A5041168206 @default.
• W3119707932 creator A5051462415 @default.
• W3119707932 creator A5056196080 @default.
• W3119707932 creator A5078284278 @default.
• W3119707932 creator A5088167860 @default.
• W3119707932 date "2021-03-01" @default.
• W3119707932 modified "2023-10-01" @default.
• W3119707932 title "Targeting Peroxisome Proliferator-Activated Receptor-α (PPAR- α) to reduce paclitaxel-induced peripheral neuropathy" @default.
• W3119707932 cites W1595757864 @default.
• W3119707932 cites W1978798118 @default.
• W3119707932 cites W1989838345 @default.
• W3119707932 cites W1998507857 @default.
• W3119707932 cites W2011523341 @default.
• W3119707932 cites W2013744734 @default.
• W3119707932 cites W2021439150 @default.
• W3119707932 cites W2026422975 @default.
• W3119707932 cites W2032621008 @default.
• W3119707932 cites W2047606780 @default.
• W3119707932 cites W2049213018 @default.
• W3119707932 cites W2059588106 @default.
• W3119707932 cites W2071620144 @default.
• W3119707932 cites W2074040841 @default.
• W3119707932 cites W2083016614 @default.
• W3119707932 cites W2087645138 @default.
• W3119707932 cites W2093167786 @default.
• W3119707932 cites W2100550253 @default.
• W3119707932 cites W2105771810 @default.
• W3119707932 cites W2138193535 @default.
• W3119707932 cites W2144118779 @default.
• W3119707932 cites W2149287982 @default.
• W3119707932 cites W2158458371 @default.
• W3119707932 cites W2164438100 @default.
• W3119707932 cites W2175088684 @default.
• W3119707932 cites W2400751176 @default.
• W3119707932 cites W2510498373 @default.
• W3119707932 cites W2591403396 @default.
• W3119707932 cites W2624064951 @default.
• W3119707932 cites W2808215604 @default.
• W3119707932 cites W2811453597 @default.
• W3119707932 cites W2892348801 @default.
• W3119707932 cites W2977007813 @default.
• W3119707932 cites W2979297062 @default.
• W3119707932 cites W2989582075 @default.
• W3119707932 cites W2996112597 @default.
• W3119707932 cites W2999417355 @default.
• W3119707932 cites W3024137762 @default.
• W3119707932 cites W3028694118 @default.
• W3119707932 cites W3089751406 @default.
• W3119707932 cites W4254185355 @default.
• W3119707932 doi "https://doi.org/10.1016/j.bbi.2021.01.004" @default.
• W3119707932 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8226373" @default.
• W3119707932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33434562" @default.
• W3119707932 hasPublicationYear "2021" @default.
• W3119707932 type Work @default.
• W3119707932 sameAs 3119707932 @default.
• W3119707932 citedByCount "19" @default.
• W3119707932 countsByYear W31197079322021 @default.
• W3119707932 countsByYear W31197079322022 @default.
• W3119707932 countsByYear W31197079322023 @default.
• W3119707932 crossrefType "journal-article" @default.
• W3119707932 hasAuthorship W3119707932A5007967344 @default.
• W3119707932 hasAuthorship W3119707932A5014707832 @default.
• W3119707932 hasAuthorship W3119707932A5015383366 @default.
• W3119707932 hasAuthorship W3119707932A5029671075 @default.
• W3119707932 hasAuthorship W3119707932A5030544754 @default.
• W3119707932 hasAuthorship W3119707932A5037907585 @default.
• W3119707932 hasAuthorship W3119707932A5038391772 @default.
• W3119707932 hasAuthorship W3119707932A5038514683 @default.
• W3119707932 hasAuthorship W3119707932A5041168206 @default.
• W3119707932 hasAuthorship W3119707932A5051462415 @default.
• W3119707932 hasAuthorship W3119707932A5056196080 @default.
• W3119707932 hasAuthorship W3119707932A5078284278 @default.
• W3119707932 hasAuthorship W3119707932A5088167860 @default.
• W3119707932 hasBestOaLocation W31197079322 @default.
• W3119707932 hasConcept C121608353 @default.
• W3119707932 hasConcept C126322002 @default.
• W3119707932 hasConcept C134018914 @default.
• W3119707932 hasConcept C170493617 @default.
• W3119707932 hasConcept C185592680 @default.
• W3119707932 hasConcept C187345961 @default.
• W3119707932 hasConcept C2776914184 @default.
• W3119707932 hasConcept C2777292972 @default.
• W3119707932 hasConcept C2778110834 @default.
• W3119707932 hasConcept C2779901536 @default.
• W3119707932 hasConcept C2781123555 @default.
• W3119707932 hasConcept C555293320 @default.
• W3119707932 hasConcept C71924100 @default.
• W3119707932 hasConcept C87753298 @default.

• next